BIRAD

BIRAD is Bar-Ilan University’s technology transfer office, charged with translating academic research from Bar-Ilan’s labs into operating companies. Its activity concentrates in biotech and pharma and therapeutics, in line with the university’s strength in life sciences and chemistry.

The thesis is anchored to the research output of Bar-Ilan University. BIRAD licenses, structures, and spins out IP from the university’s faculty, with healthcare activity focused on biotech and therapeutics, with selective interest in adjacent categories where the university’s strengths translate. AI is increasingly relevant across the portfolio as Bar-Ilan’s computational and data science capabilities intersect with biology and chemistry. The portfolio reflects an institutional preference for IP-rich companies whose defensibility lives in the underlying science rather than in commercial positioning.

Checks fall below two hundred and fifty thousand dollars at the Pre-Seed and Seed stages, structured as part of the spinout and licensing process rather than as standalone venture investments. Geography is anchored in Bar-Ilan-affiliated companies, which typically target global pharmaceutical and life sciences markets in the US and Europe. BIRAD is positioned as a foundational partner that bridges from academic discovery to the venture capital syndicates that will fund the company’s growth, and the structure of engagement reflects that role.

The team operates with the discipline of a tech-transfer office that has built a portfolio over many years. Founders engage with experienced licensing and commercialization staff, and the relationships extend deep into Bar-Ilan’s research faculty. The diligence is grounded in IP analysis, scientific defensibility, and a realistic assessment of the commercial path from foundational research to a viable therapeutic or platform company.

The value-add concentrates on the parts of company formation that academic founders most often underestimate, including IP structuring, licensing arrangements, and the institutional credibility that a structured spinout from Bar-Ilan provides to external investors. BIRAD is direct about scope. It does not engage with companies unaffiliated with Bar-Ilan University, and the relationship structure is institutional rather than conventional venture. For academic founders coming out of Bar-Ilan in biotech, pharma and therapeutics, or AI-driven life sciences, BIRAD is the natural and often essential first commercial partner. The conversations are technical and institutional, the structures reflect decades of tech-transfer practice, and the path forward usually involves bringing in venture and pharmaceutical partners quickly. BIRAD is constructive about that handoff and treats it as a sign of success rather than a loss of control. Founders who engage well tend to come out of the relationship with cleaner IP positions, more credible commercial structures, and deeper access to the venture investors who will lead the company’s first major round.